SEARCH

SEARCH BY CITATION

References

  • 1
    Haldol® injection (for immediate release) Package Insert. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2005;rev. 05.2007.
  • 2
    Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium (review), the Cochrane collaboration 2008;2. Available at: www. cochrane.org. Accessed February 2010.
  • 3
    American Psychiatric Association: practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999; 156( 5 suppl): 120, updated 2004.
  • 4
    Thomson Micromedex. 2008. Micromedex healthcare series: “haloperidol” Thomson Micromedex, Greenwood Village.
  • 5
    FDA alert: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). 2007. This alert highlights revisions to the labeling for haloperidol. Available at: www.fda.gov. Accessed February 2010.
  • 6
    Tesar GE, Murray GB, Cassem NH. Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients, J Clin Psychopharmacol. 1985; 5( 6): 344347.
  • 7
    Fricchione GL, Nejad SH, Esses JA, et al. Postoperative delirium, Am J Psychiatry. 2008; 165: 7.
  • 8
    Douglas PH, Block PC. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes, Catheter Cardiovasc Interv. 2000; 50( 3): 352355.
  • 9
    Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psych. 2001; 158( 11): 17741782.
  • 10
    Tisdale JE, Kovacs R, Mi D, et al. Accuracy of uncorrected versus corrected QT Interval for Prediction of torsade de pointes associated with intravenous haloperidol. Pharmacotherapy. 2007; 27( 2): 175182.
  • 11
    Arita Y, Kawamoto T, Shingu N. Three cases of ventricular tachycardia and torsades de pointes induced by antipsychotic drugs. Shinzo. 1997; 29( 1): 6874.
  • 12
    Herrero-Hernandez R, Cidoncha-Gallego M, Herrero-De Lucas E, Jimenez/-Lendinez YM. Haloperidol por via intravenosa y torsade de pointes. Medicina intensive. 2004; 28( 2): 89.
  • 13
    Rettmar K, Stierle U, Muhle E, et al. QT-Verlängerung und Kammerflimmern unter Haloperidol- und Clonidin-Therapie des Alkoholentzugssyndroms. Intensivmedizin und Notfallmedizin. 1992; 29( 4): 178183.
  • 14
    ARIZONA CERT, Arizona Center for Education and Research on Therapeutics. Available at: www.azcert.org. Accessed February 2010.
  • 15
    Lip G, Godtfredsen J. Cardiac arrhythmias—a clinical approach. Edinburgh: Mosby; 2003.
  • 16
    Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes—three cases and a literature review. Psychosomatics. 1995; 36: 541549.
  • 17
    Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol. 1993; 13( 2): 128132.
  • 18
    Perrault LP, Denault AY, Carrier M, Cartier R, Bélisle S. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anesth. 2000; 47( 3): 251254.
  • 19
    Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use, Expert Opin Drug Saf. 2003; 2( 6): 543547.
  • 20
    Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature, Pharmacotherapy. 1997; 17( 3): 531537.
  • 21
    O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsades de pointes. Ann Pharacother. 1999; 33( 10): 10461050.
  • 22
    Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary, Crit Care Med. 1995; 23( 9): 15961600.
  • 23
    Akers WS, Flynn JD, Davis GA, Green AE, Winstead PS, Strobel G. Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. Pharmacotherapy. 2004; 24( 3): 404408.
  • 24
    CPS Compendium of Pharmaceuticals and Specialties, the Canadian drug reference for health professionals, 2007, Canadian pharmacists association.
  • 25
    Rote Liste Deutschland 2008, Rote Liste Service GmbH Frankfurt am Main. Available at: www.rote-liste.de. Accessed February 2010.
  • 26
    Laible B, Johnson T. Delirium in the hospitalized patient: a primer for the pharmacist clinician. J Pharm Pract. 2007; 20( 5): 368372.
  • 27
    Michaud L, Büla C, Berney A, et al. Delirium: guidelines for general hospitals. J Psychosom Res. 2007; 62( 3): 371383.
  • 28
    Morandi A, Gunter ML, Ely EW, Pandharipande P. The pharmacological management of delirium in critical illness. Current Drug Therapy. 2008, 3: 148157.
  • 29
    VIDAL-l'information sur les produits de santé 2008, Issy les Moulineaux Cedex. Available at: www.vidal.fr. Accessed February 2010.
  • 30
    Haldol iniettabile—ufficiale monografia italiana. Available at: www. informatorefarmaceutico.it. Accessed February 2010.
  • 31
    Arzneimittelkompendium der Schweiz 2008, documed Verlag Basel. Availabla at: www.kompendium.ch. Accessed February 2010.
  • 32
    Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill, American College of Critical Care Medicine ACCM, Society of Critical Care Medicine SCCM, American Society of Health-System Pharmacists ASHP. Crit Care Med. 2002; 30( 1): 119141.
  • 33
    Henriques-Forsythe MN, Ivonye CC, Kamuguisha LK, Olejeme KA, Onwuanyi AE. Is telemetry overused? Is it as helpful as thought? Cleve Clin J Med. 2009; 76( 6): 368372.
  • 34
    Sivaram CA, Summers JH, Ahmed N. Telemetry outside critical care units: patterns of utilization and influence on management decisions. Clin Cardiol. 1998; 21( 7): 503505.
  • 35
    Sanders KM, Murray GB, Cassem NH. High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump. J Clin Psychopharmacol. 1991; 11( 2): 146147.
  • 36
    Ryan CJ. Haloperidol, midazolam and intravenous sedation. Aust NZ J Psychiatry. 1999; 33( 6): 942943.
  • 37
    BNF British National Formulary, compendium of pharmaceuticals and specialties of the UK. 2007. Available at: www.bnf.org. Accessed February 2010.
  • 38
    Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med. 1993; 119( 5): 391394.
  • 39
    Zeifman CWE, Friedman B. Torsades de pointes: potential consequence of intravenous haloperidol in the intensive care unit. Intensive Care World. 1994; 11( 3): 109112.
  • 40
    Di Salvo TG, O'Gara TP. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol. 1995; 18: 285290.
  • 41
    Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994: 22( 3): 433440.
  • 42
    Faigel DO, Metz DC, Kochman ML. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalances. Am J Gastroenterol. 1995; 90( 5): 822824.
  • 43
    Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998; 81( 2): 238240.
  • 44
    Tisdale JE, Rasty S, Padhi ID, Sharma ND, Rosman H. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol. 2001; 41: 13101318.
  • 45
    Stepkovitch K, Heagle Bahn C, Gupta R. Low-dose haloperidol associated QTc prolongation. J Am Geriatr Soc. 2008; 56( 10): 19631964.
  • 46
    Ginwalla M, Biblo LA, Paydak H. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block. WMJ. 2009; 108( 1): 4850.